用于改善眼周皱纹的 Alpha 和 Beta 防御素皮肤护理方案的临床试验。

Clinical Trial of Alpha and Beta Defensin Skin Care Regimen for Improvement of Periocular Wrinkles.

出版信息

J Drugs Dermatol. 2023 Sep 1;22(9):874-880. doi: 10.36849/JDD.7184.

Abstract

BACKGROUND

Defensins recruit leucine-rich repeat-containing G protein-coupled receptor 6 positive (Lgr6+) stem cells which ultimately regenerate new basal stem cells, healthy keratinocytes, and nascent hair follicles. Thus, defensins are an exciting, novel therapy for the reversal of skin aging.

METHODS

This is a multicenter, prospective, open-label clinical trial. Twenty healthy subjects, aged 45-80, with Fitzpatrick skin types II-IV were enrolled in the study. A skin care regimen containing alpha-defensin 5 and beta-defensin 3 were applied to the face twice daily for 12 weeks. This skin care regimen contains a greater percentage of defensins than that already studied.7 All participants underwent imaging at baseline, day 30, day 60, and day 90. Primary endpoints included investigator scoring on the Fitzpatrick-Goldman wrinkle scale and percent improvement in periorbital wrinkles, laxity, pigmentation, erythema, texture, and radiance. Secondary endpoints were investigator Global Aesthetic Improvement Score (GAIS), subject GAIS, and investigator assessment of tolerability. A final subject questionnaire was completed on day 90. Results: Based on the Fitzpatrick-Goldman wrinkle scale, a statistically significant improvement was noted in both wrinkling and elastosis from baseline to day 90. 30% of subjects were rated as much improved and 50% of subjects were rated as improved on the physician GAIS at the 90 day follow up. Improvements were noted in all aspects of skin quality including wrinkles, laxity, dyschromia, erythema, texture, and radiance. Conclusion: The enhanced formula containing increased concentrations of alpha-defensin 5 and beta-defensin 3 is a safe and efficacious topical therapy for the treatment of periorbital rhytids.

CITATION

Hartman N, Loyal J, Taub A, et al. Clinical trial of alpha and beta defensin skin care regimen for improvement of periocular wrinkles. J Drugs Dermatol. 2023;22(9):874-880. doi:10.36849/JDD.7184.

摘要

背景

防御素招募富含亮氨酸重复序列的 G 蛋白偶联受体 6 阳性（Lgr6+）干细胞，最终再生新的基底干细胞、健康角质形成细胞和新生毛囊。因此，防御素是一种令人兴奋的、新颖的逆转皮肤衰老的治疗方法。

方法

这是一项多中心、前瞻性、开放性临床试验。20 名年龄在 45-80 岁、皮肤类型为 Fitzpatrick II-IV 的健康受试者入组研究。一种含有α-防御素 5 和β-防御素 3 的皮肤护理方案每天两次应用于面部，持续 12 周。这种皮肤护理方案中防御素的含量比之前研究的要高。所有参与者在基线、第 30 天、第 60 天和第 90 天接受影像学检查。主要终点包括研究者根据 Fitzpatrick-Goldman 皱纹量表进行评分以及眶周皱纹、松弛度、色素沉着、红斑、质地和光泽度的改善百分比。次要终点包括研究者的整体美学改善评分（GAIS）、受试者的 GAIS 和研究者对耐受性的评估。在第 90 天完成最终的受试者问卷。结果：根据 Fitzpatrick-Goldman 皱纹量表，从基线到第 90 天，皱纹和弹性组织变性均有显著改善。30%的受试者被评为明显改善，50%的受试者在第 90 天随访时被评为改善的医生 GAIS。所有皮肤质量方面均有改善，包括皱纹、松弛度、色素异常、红斑、质地和光泽度。结论：含有更高浓度的α-防御素 5 和β-防御素 3 的增强配方是一种安全有效的眶周皱纹治疗的局部治疗方法。

参考文献

Hartman N, Loyal J, Taub A, et al. Clinical trial of alpha and beta defensin skin care regimen for improvement of periocular wrinkles. J Drugs Dermatol. 2023;22(9):874-880. doi:10.36849/JDD.7184.